GHK-Cu
GHK-Cu is a naturally occurring copper-binding tripeptide studied for extracellular-matrix remodeling, skin biology and wound repair. Its mechanistic and preclinical literature is substantial, but route matters: evidence around topical/cutaneous use should not be generalized to injectable use.
GHK-Cu supports collagen and tissue-remodeling biology, making it especially interesting for skin, hair, wound healing and recovery.
GHK-Cu is a good example of a biologically interesting compound whose broad “regenerative” reputation extends beyond the strongest human evidence.
●●○○○
Some human topical/cutaneous research exists, but the clinical literature is limited and mixed.
●●●●○
Extensive cell and animal work spans collagen, extracellular matrix, inflammation and repair.
●●●●○
Well-developed tissue-remodeling rationale, including fibroblast and matrix biology.
●●●●○
Popular across skin, hair, recovery and “regeneration” conversations.
A copper-binding peptide involved in tissue-remodeling biology.
GHK is the tripeptide glycyl-L-histidyl-L-lysine. It binds copper(II) to form GHK-Cu and has been studied in fibroblasts, extracellular matrix remodeling, wound biology and skin.
Classic human-fibroblast experiments found increased collagen and glycosaminoglycan synthesis. Those findings are biologically meaningful—but they are cell-culture evidence, not proof of a systemic anti-aging therapy.
Human evidence exists, but it is not as broad as the marketing.
A randomized 2006 study of topical copper-tripeptide skin care after CO₂ laser resurfacing had 13 completers. Objective assessments found no significant advantage for erythema, wrinkles or overall skin quality between groups, although patient-reported overall skin-quality improvement favored the GHK-Cu regimen.
A recent review of topical GHK noted a surprising lack of robust clinical studies despite widespread cosmetic use.
What it does not support: broad claims that GHK-Cu has been clinically proven to regenerate tissues throughout the body.
This is where GHK-Cu’s evidence is strongest.
Human fibroblast studies have reported effects on collagen synthesis, glycosaminoglycans and extracellular-matrix remodeling. Animal and laboratory models have extended the research into wound healing, angiogenesis and inflammatory biology.
These mechanisms help explain the scientific interest. They do not establish that every route, formulation or “regenerative” use produces clinically meaningful human outcomes.
One molecule, several different stories.
GHK-Cu appears in discussions of skin quality, hair, wound repair, injury recovery and longevity. Those use cases should not be treated as one evidence category.
Where the story gets stretched.
What people are actually reporting.
Recurring community-use patterns are visible around GHK-Cu. We document those patterns here without turning them into a clinical recommendation.
Injectable GHK-Cu discussions commonly cluster around roughly 1–2.5 mg per day, with 2 mg/day appearing frequently. Topical GHK-Cu is a separate use pattern and should not be interpreted through injectable amounts.
There is no clinically established injectable GHK-Cu dosing protocol for skin, hair, recovery or longevity. FDA notes limited human data for injectable GHK-Cu and potential immunogenicity and peptide-impurity concerns. Topical research cannot establish the safety or dose of injected GHK-Cu.
FDA treats injectable GHK-Cu differently.
FDA’s current compounding safety-risk page says compounded injectable GHK-Cu may pose immunogenicity risk because of aggregation and peptide-related impurities, and that human data are limited for safety considerations.
FDA’s May 2026 503A update places GHK-Cu for non-injectable routes in Category 1 (under evaluation) and says the agency intends to consult its Pharmacy Compounding Advisory Committee regarding potential inclusion of GHK-Cu on the 503A Bulks List before the end of February 2027.
WIDE
The strongest story is tissue-remodeling biology. The widest gap appears when that biology—and limited topical human research—is generalized into systemic regeneration, injury recovery or longevity claims.
A new wound-healing platform study—not new injectable proof.
Preclinical
GHK-Cu was incorporated into a multi-component hydrogel for diabetic wound repair.
A Carbohydrate Polymers study combined GHK-Cu with a chitosan/oxidized-alginate hydrogel, glucose oxidase and tea-derived exosomes. In laboratory and animal models, the system improved the hostile wound microenvironment and supported antibacterial activity, oxygenation, angiogenesis and repair.
Key sources behind the profile.
Read the new study.
Put GHK-Cu in context.
Recovery
Separate tissue-remodeling biology from demonstrated human recovery outcomes.
Longevity
See why regenerative mechanisms are not automatically anti-aging outcomes.